cavosonstat
Phase 2- Indications
- Chronic obstructive pulmonary disease
Company intelligence / Profile preview
GSNOR Therapeutics
Washington, United Stateslinknovate.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
GSNOR Therapeutics has developed small molecule inhibitors of the GSNOR enzyme. Their lead compound GTI‑850 has shown strong suppression of autoimmunity and pro-inflammatory mediators in preclinical models of rheumatoid arthritis. Another compound, Cavosonstat, reached Phase 2 clinical trials for COPD but current status unknown. The company’s approach aims to provide improved safety and efficacy over existing therapies by targeting a novel mechanism.
- Therapeutic areas
- PulmonologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on GSNOR Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSNOR Therapeutics.